| 01/31 | Eisai-Biogen Gets Priority Review for Alzheimer's Drug in Japan | MT |
| 01/30 | Global markets live: Toyota, Unilever, Bayer, Goldman Sachs, Biogen... | |
| 01/30 | It's all about central banks this week | |
| 01/30 | Eisai-Biogen Partnership Pursues Marketing Authorization of Alzheimer's Drug in Europe | MT |
| 01/30 | Biogen, Eisai Drug Lecanemab Gets Priority Review Status in Japan | MT |
| 01/29 | Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen | RE |
| 01/29 | Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen | RE |
| 01/29 | Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in J.. | CI |
| 01/27 | Disappointing Tech Earnings, Outlook Weigh on Exchange-Traded Funds, Equity Futures Pre.. | MT |
| 01/27 | Biogen, Eisai Say European Medicines Agency Accepts for Review Regulatory Application f.. | MT |
| 01/26 | Eisai : Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer.. | AQ |
| 01/26 | BioArctic, Eisai's Regulatory Application for Alzheimer's Disease Drug Accepted in EU | MT |
| 01/26 | Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization | DJ |
| 01/26 | European Medicines Agency accepts Marketing Authorization Application for lecanemab as .. | AQ |
| 01/26 | Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early .. | CI |
| 01/26 | Eisai Co., Ltd. and Biogen Inc. Announce European Medicines Agency Accepts Marketing Au.. | CI |
| 01/25 | Lonza underscores growth prospects with share buy-back, dividend hike | RE |
| 01/23 | Sinking Yen, Wall Street Cues Drive Tokyo Shares Higher | MT |
| 01/20 | Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts | RE |
| 01/19 | Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug | RE |
| 01/17 | Eisai : Aims to advance gastrointestinal cancer treatment with research across multiple tu.. | PU |
| 01/17 | Eisai, Biogen Seek Approval for Alzheimer's Drug in Japan | MT |
| 01/16 | Yen Boost, Prospect of Monetary Policy Shift Spook Japanese Traders; Daiichi Sankyo Fil.. | MT |
| 01/16 | Japan's Nikkei ends at more than a week low as BOJ capitulation bets push up yen | RE |
| 01/15 | Japan's Nikkei dives 1% as BOJ capitulation bets push up yen | RE |
| 01/15 | Eisai files for approval of Alzheimer's drug in Japan | RE |
| 01/15 | BioArctic, Eisai Submit Regulatory Application for Alzheimer's Disease Drug in Japan | MT |
| 01/15 | Eisai, Biogen apply for Alzheimer's drug approval in Japan | AQ |
| 01/15 | Eisai files for approval of Alzheimer's drug in Japan | RE |
| 01/15 | Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofi.. | CI |
| 01/12 | Eisai : Launches renewed sustainability page | PU |
| 01/12 | Modalis Therapeutics Corporation Announces Notice of Termination of A Research Collabor.. | CI |
| 01/10 | BioArctic, Eisai Seek EU Nod For Early Alzheimer's Disease Drug | MT |
| 01/10 | BioArctic's partner Eisai submits marketing authorization application for lecanemab as .. | AQ |
| 01/10 | Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early .. | CI |
| 01/10 | Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanem.. | CI |
| 01/10 | Japan's Nikkei closes at 2-week high on tech boost | RE |
| 01/09 | Japan's Nikkei gains as tech shares track U.S. peers higher | RE |
| 01/09 | Global markets live: Alibaba, Qiagen, Macy's, Oracle, Chevron... | |
| 01/09 | Trending: Biogen, Eisai Win FDA Nod for Alzheimer's Drug | DJ |
| 01/09 | Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approva.. | AQ |
| 01/09 | Eisai, Biogen's Alzheimer's drug price should not dent demand - analysts | RE |
| 01/09 | FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Tr.. | AQ |
| 01/09 | MarketScreener's World Press Review: January 9 | |
| 01/08 | Eisai, Biogen Get US Drug Regulator's Nod for Alzheimer's Drug | MT |
| 01/08 | BioArctic, Eisai Secure US FDA Approval For Alzheimer's Disease Drug | MT |
| 01/08 | Reuters-schedule/… | RE |
| 01/07 | Explainer : New drug slows Alzheimer's but comes with caveats | AQ |
| 01/07 | Reuters-schedule/… | RE |
| 01/07 | Transcript : Eisai Co., Ltd. - Special Call | CI |
| 01/06 | Eisai : Submits Supplemental Biologics License Application to FDA for Traditional Approval.. | PU |
| 01/06 | Eisai files for full FDA approval for Alzheimer's drug Leqembi | RE |
| 01/06 | BioArctic's partner Eisai submits supplemental Biologics License Application to FDA for.. | AQ |
| 01/06 | U.S. regulators OK Alzheimer's drug developed by Japan's Eisai | AQ |
| 01/06 | Factbox-Who can get the newly approved Eisai and Biogen Alzheimer's drug? | RE |
| 01/06 | US approves Alzheimer's drug that modestly slows disease | AQ |
| 01/06 | ADRs End Higher, Shell and Eisai Trade Actively | DJ |
| 01/06 | Wall St rallies as jobs, services data calm rate hike worries | RE |
| 01/06 | Alzheimer's drug that modestly slows disease OK'd by FDA | AQ |
| 01/06 | Eisai : FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathwa.. | PU |
| 01/06 | Eisai says new Alzheimer's drug to cost $26,500 annually | RE |
| 01/06 | Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under th.. | CI |
| 01/06 | Eisai Co., Ltd. Announces LEQEMBI (Lecanemab-Rimb) Has the Potential to Make Difference.. | CI |
| 01/06 | U.S. FDA approves Eisai, Biogen's Alzheimer's drug | RE |
| 01/06 | U.S. FDA approves Eisai, Biogen's Alzheimer's drug | RE |
| 01/05 | Biogen splits R&D division ahead of key decision on Alzheimer's drug | RE |
| 01/04 | Japan's Nikkei tracks Wall St weakness to end at near 10-month low | RE |
| 01/03 | Japan's Nikkei hits over 3-month low tracking subdued Wall Street | RE |
| 2022 | Yasuda Logistics Corporation (TSE:9324) agreed to acqu.. | CI |
| 2022 | Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report | RE |
| 2022 | Biogen's Partner Eisai Begins Biologics License Application for Lecanemab in China | MT |
| 2022 | BioArctic's partner Eisai publishes statement relating to article on lecanemab in Scien.. | AQ |
| 2022 | Japan drugmaker Eisai's shares slump after report of 3rd death in Alzheimer's trial | RE |
| 2022 | Japan's Nikkei slips as chip stocks weigh, set for worst week since June | RE |
| 2022 | Eisai Initiates BLA Submission of Data for Lecanemab in China | CI |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
